This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Bone Metabolism Therapeutics Market To 2018 - Hyperparathyroidism Sector To Decline In The Absence Of New Product Launches And Increased Generic Erosion For Zemplar, Hectorol And Sensipar

Figure 26: Paget's Disease of Bone Therapeutics Market, Global, Treatment Usage Patterns (millions), 2002-2018 46

Figure 27: Paget's Disease of Bone Therapeutics Market, Treatment Flow Algorithm 48

Figure 28: Paget's Disease of Bone, Market Drivers and Barriers 49

Figure 29: Hyperparathyroidism Therapeutics Market, Global, Revenue Forecasts ($m), 2002-2018 50

Figure 30: Hyperparathyroidism Therapeutics Market, Global, Revenue Analysis by Geography ($m), 2002-2018 52

Figure 31: Hyperparathyroidism Therapeutics Market, Global, Branded vs. Generic Share, 2010 and 2018 54

Figure 32: Hyperparathyroidism Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2018 55

Figure 33: Hyperparathyroidism Therapeutics Market, Global, Treatment Usage Patterns (millions), 2002-2018 56

Figure 34: Hyperparathyroidism Therapeutics Market, Treatment Flow Algorithm 58

Figure 35: Hyperparathyroidism, Market Drivers and Barriers 59

Figure 36: Bone Metastases Therapeutics Market, Global, Revenue Forecasts ($m), 2002-2018 61

Figure 37: Bone Metastases Therapeutics Market, Global, Revenue Analysis by Geography ($m), 2002-2018 62

Figure 38: Bone Metastases Therapeutics Market, Global, Branded vs. Generic Share, 2010 and 2018 64

Figure 39: Bone Metastases Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2018 65

Figure 40: Bone Metastases Therapeutics Market, Global, Treatment Usage Patterns (thousands), 2002-2018 66

Figure 41: Bone Metastases Therapeutics Market, Treatment Flow Algorithm 68

Figure 42: Bone Metastases, Market Drivers and Barriers 69

Figure 43: Bone Metabolism Therapeutics Market, Global, R&D Pipeline by Indication (%), 2011 70

Figure 44: Bone Metabolism Therapeutics Market, Global, R&D Pipeline by Phase (%), 2011 71

Figure 45: Bone Metabolism Therapeutics Market, Global, SWOT - Amgen Inc. 88

Figure 46: Bone Metabolism Therapeutics Market, Global, SWOT - Abbott Laboratories 89

Figure 47: Bone Metabolism Therapeutics Market, Global, SWOT - Genzyme Corporation 90

Figure 48: Bone Metabolism Therapeutics Market, Global, SWOT - Merck & Co., Inc. 92

Figure 49: Bone Metabolism Therapeutics Market, Global, SWOT - Novartis AG 94

Figure 50: Bone Metabolism Therapeutics Market, Global, Deals by Indication, 2009-2011 95

9 of 10

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,079.57 -42.44 -0.25%
S&P 500 1,996.74 -3.38 -0.17%
NASDAQ 4,557.6950 -11.9260 -0.26%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs